Purple Biotech Reports Q1 2025 Financial Results and Advances Clinical Programs

Purple Biotech ( (PPBT) ) has issued an update.

On May 21, 2025, Purple Biotech reported its financial results for the first quarter of 2025, highlighting significant progress in its clinical programs. The company presented final Phase 2 data for its CM24 study at the AACR Annual Meeting 2025, showing statistically significant efficacy in biomarker subgroup analyses, which will inform patient selection for an upcoming Phase 2b study. Additionally, the NT219 Phase 2 study in head and neck cancer is on track, with promising data presented at the same conference. The company also announced a research collaboration with the Icahn School of Medicine at Mount Sinai to explore its CAPTN-3 tri-specific antibody platform. Financially, Purple Biotech reported a decreased operating loss due to reduced research and development expenses and maintained a cash runway into mid-2026.

The most recent analyst rating on (PPBT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.

Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage biotechnology company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company is engaged in advancing its pipeline of innovative cancer treatments, including CM24 and NT219, with a market focus on enhancing the efficacy of existing cancer therapies and addressing unmet medical needs in oncology.

Average Trading Volume: 105,543

Technical Sentiment Signal: Sell

Current Market Cap: $6.62M

See more data about PPBT stock on TipRanks’ Stock Analysis page.